Evvy Raises $40M Series B to Advance Women's Health Research Through Vaginal Microbiome Data

Evvy Closes $40M Series B Funding Round

Women's health tech company Evvy announced on Tuesday the completion of a $40 million Series B funding round, led by Catalio Capital Management. The capital will support the company's women's health research and product development centered on vaginal microbiome data.

Women's health has long been a relatively underserved area within medical research — particularly in the niche of reproductive microbiome science. The size of this funding round and the profile of its lead investor reflect growing capital market interest in data-driven women's health as a category.

The Research Value of Vaginal Microbiome Data

Evvy's core focus is vaginal microbiome data. Microbiome research has already made significant strides in gut health, and the vaginal microbiome is closely linked to women's reproductive health, infection risk, chronic inflammation, and even fertility.

By testing and analyzing large-scale user samples, Evvy has the opportunity to build a dataset on female reproductive health that has historically been quite scarce. This type of data can not only improve personalized health recommendations but may also serve as a foundational resource for advancing women's health research more broadly.

A vaginal microbiome dominated by Lactobacillus is generally considered healthy — these bacteria produce lactic acid that maintains an acidic vaginal environment (pH 3.8–4.5), inhibiting the overgrowth of harmful microorganisms. When this balance is disrupted, it can lead to common conditions such as bacterial vaginosis (BV) and yeast infections, and is associated with more serious health outcomes including elevated preterm birth risk and increased susceptibility to sexually transmitted infections. Unlike gut microbiome research — where greater diversity is typically viewed as beneficial — vaginal microbiome health does not follow the same logic. This counterintuitive distinction makes the research more challenging and purpose-built datasets particularly scarce. Large-scale cohort data focused specifically on the vaginal microbiome remains limited globally, which is precisely the differentiated space Evvy is targeting.

Capital and the FemTech Landscape

The decision by Catalio Capital Management to lead this round signals that specialized investment firms are bullish on business models that combine biological data capabilities with women's health needs. For a field that has long suffered from a research gap, adequate funding can accelerate clinical validation, scale data collection, and round out the product ecosystem.

From an industry perspective, Evvy's raise is yet another example of FemTech continuing to attract capital. As data-driven approaches deepen their role in healthcare, precision health services built around specific populations are carving out new growth opportunities.

FemTech as a standalone investment category has steadily gained recognition over the past decade. According to industry research estimates, the global FemTech market is projected to exceed $60 billion around 2030, spanning segments including fertility tracking, menopause management, pelvic floor health, and reproductive disease diagnostics. Factors driving growth in this space include rising consumer demand among women for personal health data, declining costs of at-home testing technologies, and the hunger of medical AI for female-specific datasets. That said, the sector also faces headwinds — including unclear regulatory pathways, long clinical validation cycles, and strict user privacy requirements — making companies that can accumulate real-world datasets particularly well-positioned to build durable competitive moats.

Summary

Given the limited information currently available, further details about this round — such as the specific use of funds, product roadmap, and full list of participating investors — have not yet been disclosed. But based on Evvy's positioning, the company is clearly working to leverage vaginal microbiome data to fill a significant gap in women's health research. This is a direction worth watching closely as it develops.